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WHAT THIS PAPER ADDS
 Customized Aortic Repair may prove an exciting new endovascular treatmentmodality to exclude different types of aneurysms. The
concept of aneurysm sac ﬁlling has proven to be feasible in several in vitro and in vivo set-ups. Before clinical application of this
treatment can take place, the biocompatibility, biostability and the thrombogenicity have to be indisputable.
 This current study shows that the elastomer has a thrombogenicity, comparable to the golden standard of (endo-) vascular graft-
material expanded polytetraﬂuoroethylene (ePTFE) according to ﬁbrinopeptide A (FPA) and P-selectin measurements. The elas-
tomer tubes seem superior to the ePTFE tubes with regard to adhesion of platelet aggregates.a r t i c l e i n f o
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Objectives: Customized Aortic Repair (CAR) is a new concept for endovascular aortic aneurysm repair in
which a non-polymerised elastomer is injected to ﬁll the aneurysm sac around a balloon catheter.
Amongst other variables, the thrombogenicity of the elastomer should be tested, before further clinical
experiments can take place. The aim of this human ex vivo study was to measure the thrombogenicity of
the elastomer and to compare it to expanded polytetraﬂuoroethylene (ePTFE).
Design and materials: In a validated ex vivo model, non-anticoagulated blood was drawn from the
antecubital veins of 10 healthy donors with a 19-gauge needle. It was drawn through elastomer tubes
and through ePTFE Gore-Tex vascular grafts, both 60 cm long and with an inner diameter of 3 mm.
Methods: Fibrinopeptide A (FPA) and P-selectin expression was measured in blood samples, collected at
the end of the grafts. After the experiments, the deposition of platelets and ﬁbrin onto the grafts was
visualised by scanning electron microscopy.
Results: For these graft types, a progressive increase in FPA production was observed in time. No
signiﬁcant difference was observed between the elastomer and ePTFE grafts (p > 0.05). No increase in P-
selectin expression, and thereby no platelet activation, was observed in the perfusate of either grafts
(p > 0.05). By scanning electron microscopy, numerous platelet aggregates were observed on the ePTFE
grafts, whereas just a few adhered platelets and no aggregates were observed in the elastomer grafts.
Conclusions: The elastomer in its current formulation has a low thrombogenicity, comparable to ePTFE,
making it an ideal substance for endovascular aneurysm sac ﬁlling. Further research should clarify the
feasibility of CAR in vivo.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.an der Steenhoven).
ciety for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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other arterial aneurysms has become a well-established treatment
modality.1,2 However, there are still several drawbacks to EVAR.
Endoleaks, endotension, stent migration and stent failure are
complications that might lead to re-interventions, prolonged
follow-up or even rupture after treatment.3,4 Furthermore, EVAR
has anatomical restrictions. In the literature, up to 27% of aneu-
rysms are considered to be unsuitable for EVAR because of
insufﬁcient neck length, large neck diameter or severe
angulation.5
To overcome these anatomical disadvantages, Customized
Aortic Repair (CAR, a concept formerly known as Aortic Customize)
was developed as a new approach for aneurysm repair (Fig. 1).6e8
With this concept, the lumen of the aneurysm is excluded by one
or more endovascular balloon(s), and a non-polymerised liquid
elastomeric solution (polydimethylsiloxane, PDMS) is used to ﬁll
the aneurysm sac around the balloon catheter. After the in situ
polymerisation and balloon deﬂation, an endoluminal mould with
a patent lumen excludes the aneurysm sac.
One of the key attributes of this newly engineered elastomer is
its low viscosity enabling injection into the aneurysm sac through
small proﬁle (7 Fr) endovascular catheters, resulting in a fully
percutaneous, rapid and easily accessible technique. Filling the
cavity of the aneurysm sac with an injectable biocompatible elas-
tomer reduced wall stress and thereby will probably reduce the
chance of rupture risk, as aneurysm rupture occurs when the local
wall stress exceeds the local wall strength.7,9,10 Extensive in vitro
and preliminary in vivo porcine experiments have shown the
feasibility and potential of CAR.7,8,11 The elastomer has the physical
properties necessary for endovascular injection and successful
aneurysm exclusion.Figure 1. Customized Aneurysm Repair, the treatment concept: A. A schematic
drawing of an abdominal aortic aneurysm. B. A ﬁll catheter is inserted through
a femoral artery C. An endovascular balloon excludes the aneurysm from the circula-
tion. D. The two components of the elastomer are pumped in the excluded aneurysm.
Excess blood is pushed out alongside the balloon. E. After the aneurysm is ﬁlled, the
elastomer takes 5 min to cure. F. When the elastomer has cured, the endovascular
balloon is deﬂated, leaving the aneurysm excluded with a new lumen. Reproduced
with permission from Bosman et al. EJVES 2010;40:65e70.The direct contact with blood requires a low thrombogenicity of
the elastomer to prevent occlusive thrombosis or embolisation.
Regular PDMS has proven its low thrombogenic properties in the
past when compared to expanded polytetraﬂuoroethylene
(ePTFE).12 The elastomer used in CAR is very similar to regular
PDMS. However, there are no data available on the thrombogenicity
of this particular elastomer. In advance of any in vivo animal
experiments or human clinical procedures, further basic research
on the thrombogenicity must be performed.
The aim of this human ex vivo study was to measure the
thrombogenicity of the elastomer in healthy young volunteers and
compare it to the thrombogenicity of ePTFE grafts, one of the most
used materials in synthetic arterial grafts for aneurysm repair and
peripheral bypasses.Material and Methods
Ex vivo model
In a validated and earlier described ex vivo model, non-
anticoagulated blood was drawn from the antecubital veins of 10
healthy donors with a 19-gauge needle (Fig. 2).13 A vascular graft
with a length of 60 cm and a diameter of 3 mm was connected to
the needle. Using a syringe pump, blood was aspirated with
a constant ﬂow rate of 20 ml min1, for 6 min. The combination of
this diameter and ﬂow rate resulted in a shear rate of 74 s1, which
reﬂects venous ﬂow conditions and favours ﬁbrin-rich clot forma-
tion. A cuff was wrapped around the upper arm to ensure
a constant pressure of 45 mmHg, resulting in a continuous blood
ﬂow through the graft during the experiment.
All volunteers were healthy male subjects, who had no vascular
history and had no coagulopathy. The median age of the volunteers
was 24.3 (range: 22e26) years. They denied taking any medication
2 weeks before the experiment and gave informed consent. The
experiments were approved by the local medical ethics committee
(UMCU, Utrecht, the Netherlands). Every volunteer served as his
own control. Randomisation of the grafts for ﬁrst and second run
took place. When the elastomer graft was used for the ﬁrst run, the
ePTFE graft was used for the second run. This second run was
performed within half an hour of the ﬁrst and blood was drawn
from the contralateral arm.Figure 2. Ex vivo perfusion model using a cuff at a constant pressure of 45 mmHg to
ensure blood ﬂow. Blood is aspirated through the graft with a constant ﬂow of 20 mL/
min, resulting in a shear rate of 74/s.
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The elastomer tubes were cast using a custom-made mould
(Department of Fine Mechanics, Leiden University Medical Center,
Leiden, the Netherlands). The elastomer was a two-component
room-temperature addition-cure liquid silicone formulation,
obtained from Viazym BV (ViaZym BV; Delft, the Netherlands).6 The
two components consisted of:
1. A platinum-containing vinyl-terminated PDMS, surface-treated
amorphous silica and vinyl Q.
2. A methylhydro-dimethyl-siloxane copolymer containing vinyl-
terminated PDMS, surface-treated amorphous silica and vinylQ.
The two components of the elastomer were mixed using a static
mixer and injected in the mould, creating solid elastomer tubes
60 cm long with an inner diameter of 3 mm.
Standard ePTFE Gore-Tex vascular grafts (Gore, Flagstaff, AZ,
USA) with an internal diameter of 3 mm and a length of 60 cmwere
used for comparison.Blood samples and assays
Blood samples (900 ml) were collected at the end of the graft,
starting directly after connection to the vein and thereafter every
minute for a total of 4 min. After 4 min, samples were collected
every 30 s until the end of the perfusion (total perfusion time was
6 min for each arm). The samples were mixed immediately with
100 ml of 0.5 M ethylenediamine tetraacetic acid (EDTA) and
centrifuged at 3500 rpm for 5 min, and aliquots of plasma were
stored at 20 C until assayed.
Fibrinopeptide A (FPA) and P-selectin levels were determined in
the blood samples. FPA is the product from the transformation of
ﬁbrogen in ﬁbrin, which is a process activated by thrombin release.
P-selectin is a cell-adhesion molecule on the surfaces of activated
endothelial cells, which line the inner surface of blood vessels, and
activated platelets. When endothelial cells are activated by mole-
cules such as thrombin or histamine during injury or inﬂammation,
P-selectin moves from an internal cell location to the endothelial
cell surface. Therefore FPA- and P-selectin-positive platelets are an
adequate method to measure the advance of the activated coagu-
lation process.
For the FPA measurements, a commercially available enzyme-
linked immunosorbent assay was used as an indicator of ﬁbrin
formation (Zymutest FPA; Hyphen Biomed, Andresy, France).
P-selectin expression on perfused platelets, as an indicator of acti-
vation of platelets, was determined in EDTA anti-coagulated whole
blood before plasma centrifugation. Platelet activation was assayed
by ﬂow cytometric analysis using a phycoerythrin (PE)-conjugated
monoclonal antibody according to the instructions of the manu-
facturer (BD Pharmingen, San Diego, CA, USA, Catalog No 555524).Figure 3. Fibrinopeptide A measurements show a progressive increase in ﬁbrin
formation in time during ex vivo perfusions. No signiﬁcant differences were found
between the two types of grafts. Error bars indicate standard error of the mean.Scanning electron microscopy
The deposition of platelets and ﬁbrin onto the grafts was
visualised by scanning electron microscopy. The distal end of the
graft was cut into small pieces (5  5 mm), ﬁxed in 2% glutaral-
dehyde, and then dehydrated through increasing concentrations of
ethanol (80e100%). The samples were dried with the use of hex-
amethyldisilazane. Next, the graft pieces were sputter-coated with
a thin layer of platinum/palladium and analysed with scanning
electron microscopy (Philips XL30; Eindhoven, the Netherlands).Statistical analysis
The results were analysed with a paired t test, as implemented
in the statistics program Statistical Package for the Social Sciences
(SPSS) 16.0 for Windows (SPSS Inc., Chicago, IL, USA). The results
were expressed as the mean  standard error of the mean (SEM). A
P value < 0.05 was considered signiﬁcant.
Results
In the current ex vivo model, non-anticoagulated blood was
drawn directly from the antecubital veins over either Gore-Tex
ePTFE grafts or elastomer grafts (Fig. 1). All 10 perfusions were
performed without any technical or subject-related complications.
FPA concentration was measured in plasma samples taken at
different time points. For both graft types, a progressive increase in
FPA production was observed in time. No signiﬁcant difference
(P> 0.05) was observed between elastomer and ePTFE grafts (Fig. 3,
Table 1).
The activation of platelets during blood drawing was analysed
by measuring the percentage of P-selectin-positive platelets. No
increase (P > 0.05), and thereby no platelet activation, was
observed in the perfusate of either graft (Fig. 4, Table 1).
We also analysed the results by using each volunteer as his own
control, as one arm was used for an ePTFE graft and the other arm
for an elastomer graft. Fig. 5 shows the mean differences (delta
values) in FPA- and P-selectin levels per patient. These delta values
were obtained by subtracting the ePTFE measurements from the
elastomer values.
By scanning electron microscopy, numerous platelet aggregates
were observed on the ePTFE grafts whereas only a few adhered
platelets and no aggregates were observed in the elastomer grafts
(Fig. 6).
Discussion
The measurements of FPA concentration and of P-selectin-
positive platelets show that the elastomer, designed and tailored
for CAR, has a low thrombogenicity. We found no statistically
signiﬁcant difference in thrombogenicity compared to ePTFE, one
of the most used materials in synthetic arterial grafts for aneurysm
repair and peripheral bypasses (Figs. 3 and 4, Table 1).
The differences in measured FPA levels and P-selectin percent-
ages per patient were minimal as shown in Fig. 5. Individuals who
had a ‘strong’ thrombogenic response to ePTFE also had a ‘strong’
thrombogenic response to the elastomer. In the same manner,
Table 1
p-values of differences in FPA- and P-selectin levels measured at different time
points. The results were analyzed with a paired t test.
FPA P-selectin
Time (s) p p
0 0.72 0.44
1 0.94 0.58
2 0.88 0.74
3 0.97 0.48
4 0.90 0.53
4.5 0.33 0.68
5 0.26 0.74
5.5 0.71 0.28
6 0.66 0.60
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response to the elastomer.
The electron microscopic analysis showed a decrease in platelet
adhesion and aggregation on the elastomer samples compared to
ePTFE grafts (Fig. 6). Unfortunately, it was not possible to quantify
these results. The extremely smooth surface of the elastomer graft
compared to the porosity of the ePTFE graft could have contributed
to this difference in the adhesion of platelets. As the use of ePTFE
grafts in an aortic position has a low thrombosis rate, similar low
thrombosis rates can be expected with the use of the elastomer.
Limitations of the study
To measure the thrombogenicity of the elastomer, a previously
validated human ex vivo set-up was used.13 The main advantage of
this ex vivo set-up is that the blood of the volunteer does not come
in contact with surfaces other than the materials investigated.
Furthermore, in this set-up, every volunteer was his own control.
However, we appreciate the fact that every ex vivo experiment is
a simpliﬁcation of the complex in vivo situation. The small diameter
(3 mm) of the grafts we used is not comparable to the diameter of
the lower abdominal aorta (19 mm). However, increased throm-
bogenicity and vessel occlusion is especially a problem occurring in
small-diameter vessels as shear stress increases and therefore
platelet activation and deposition increase. When a small, 3-mm-
diameter graft shows only moderate platelet aggregation or ﬁbrin
depositions, it is likely that awider lumen (e.g., 10e20mm)will not
show increased thrombogenicity.
Another differencewith the in vivo situationwas the average age
(24.3 years) of the test subjects, while the average age of anFigure 4. P-selectin expression as a measure of platelet activation during ex vivo
perfusion. No signiﬁcant increase was observed between the two types of grafts. Error
bars indicate standard error of the mean.aneurysm patient is higher (average age 60e80 years). The use of
this young age group creates an unreal scenario, with regard to the
thrombogenicity in the targeted patient group. A young age group
was however chosen to be sure that the subjects were free of
coagulopathic diseases and were not on medication that possess
thrombogenic properties. For that same reason, male subjects were
chosen, as they certainly do not take oral anticonceptives. The high
thrombogenicity in this group of young, healthy volunteers would
be a major drawback of the new technique and would directly limit
the use of the elastomer in vivo. Furthermore, the use of this age
group as test subjects is a validated method in comparable
thrombogenicity studies.13 It would certainly be interesting for
future experiments to repeat the experiments in a more senior age
group.
A potential shortcoming of the set-up might be the hypothetical
activation of the coagulation cascade when the ﬁrst run of sample
collection takes place. This might inﬂuence the measurements
during the second run. In this study and in the earlier study with
the same ex vivo model, no difference was shown in baseline FPA
levels in both runs, indicating that systemic coagulation activation
by the procedure is unlikely.13 In addition, the randomisation of the
grafts used in the ﬁrst and second run should have corrected for
this potential bias.Customized Aortic Repair
CAR has been developed to overcome the shortcomings of EVAR,
as stated above. In an in vitro set-up, it has proven to signiﬁcantly
reduce aneurysmal wall stress.7 When endovascular balloons
become available in different forms and conﬁgurations, in theory,
any aneurysm with a deviant anatomy will be treatable with
endovascular techniques using elastomer sac ﬁlling.
Although new EVAR grafts (e.g., the Endurant and the Aorﬁx)
have been launched, which prove the ability to treat severe angu-
lations,14,15 with many of the current EVAR techniques, severe
angulations may still lead to kinking of the graft material and
eventually to migration of the graft.16e18 As no additional sup-
porting graft material is used, these problems are not likely to occur
with CAR. The ﬂuidity of the non-polymerised elastomer inherently
causes adjustment to the geometry of the aneurysm, not only by
ﬁlling the large cavity of the aneurysm sac but also by diffusing into
all irregularities and side holes. The elastomer mould will attach
itself as it customises itself to the form of the abdominal aorta
aneurysm (AAA) sac.
Angulation and occlusive disease of the iliac arteries are an
important exclusion criterion for EVAR, and tortuosity may form
a serious obstacle for a successful EVAR procedure. A minimal
diameter of 12e22 Fr is often needed to access the bulky and rigid
delivery sheath. To ﬁll the sac with the biocompatible elastomer,
a catheter of only 7 Fr is needed. Preliminary in vivo porcine
experiments have shown that this concept is technically feasible.8
Besides the treatment of AAAs, CAR may prove a possible
treatment modality for thoracic-aorta aneurysms, peripheral
aneurysms and iliac aneurysms. With the current EVAR techniques,
iliac aneurysms can sometimes be difﬁcult to treat due to short
distal sealing areas, leading to coiling and overstenting of the
internal iliac artery. With the CAR concept, there is no necessity for
a long landing area, and this may prevent the necessity to overstent
the iliac artery, thereby preventing the introduction of buttock
claudication and ischaemia.
Beside the stand-alone treatment concept, the elastomer
injection technique is more broadly applicable. The elastomer can
already be used as an adjuvant with current stent grafts when
problems of endoleak or migration occur. In these cases, the
Figure 5. Graph depicting the the difference in the levels of FPA- and P-selectin levels in each patient (Elastomer value eePTFE value). Error bars show SD. The delta values were
obtained by subtracting the ePTFE measurement from the elastomer measurement in each patient.
Figure 6. Scanning electron microscopy of grafts from one single donor. The red circles show platelet adhesion and aggregation on the grafts after 6 min of perfusion with non-
anticoagulated blood. On the left, the ePTFE specimen, on the right, the elastomer specimen. Pictures are representative for all healthy volunteers.
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endovascular stentgraft.11,19
The CAR concept is not the only aneurysm treatment concept
that addresses aneurysm cavity ﬁlling. Early in vivo human results
with the Nellix have been recently published and show promising
results.20 The Nellix concept uses ‘bag-ﬁlling’ to ﬁxate its 20 Fr
grafts with endo-bags in the aneurysm cavity. Although it may
seem very similar, it is a different concept than the concept pre-
sented in the current manuscript, as it always needs a bulky graft
for aneurysm exclusion. Furthermore, the polymer is injected in
a closed endo-bag instead of ‘free-range’, thereby limiting its
‘customising’ capabilities. Nevertheless, the Nellix graft has very
promising results and may prove to be an excellent addition to the
abdominal aneurysm treatment modalities.
The elastomer
The elastomer used in this study was designed for aneurysm sac
ﬁlling in CAR.6e8,11 It consists of PDMS which has a widespread use
in multiple in vivo applications. PDMS is a biocompatible elastomer,
and grafts coated with PDMS have shown less graft stenosis
compared with other grafts.12,21e25 The current formula is non-
toxic and the product cross-links isothermally in the presence of
blood, without the release of toxic by-products. Viscosity of the
compound allowed infusion rates of up to 2 ml s1 using a standard
angiographic pump with an injection pressure up to 1200 pounds
per square inch. The substance has an average polymerisation time
of approximately 5 min. After curing, the material had a yield stress
of approximately 400 kiloPascal (kPa), failing at more than 20%
elongation. The density of the cured elastomer is 1.0167 g cm3.
More details about the development of the current elastomer can
be found in an earlier publication.8Clinical relevance
CAR may prove to be an exciting new endovascular treatment
modality to exclude different types of aneurysms. As mentioned
above, the concept of aneurysm sac ﬁlling is feasible in several
in vitro and in vivo set-ups.7,8,11,19 Before clinical applications can
take place, the biocompatibility, biostability and the thromboge-
nicity have to be indisputable. The current study showed that the
elastomer has, according to FPA- and P-selectin measurements
(Figs. 3 and 4), a thrombogenicity comparable to ePTFE, the
preferred material in synthetic (endo-) vascular grafts. The elas-
tomer tubes seem to be superior to the ePTFE tubes with regard to
adhesion of platelet aggregates (Fig. 6).Conclusions
In conclusion, the elastomer in its current formulation6 has a low
thrombogenicity, comparable to the thrombogenicity of ePTFE, in an
ex vivo human model. This property makes it an ideal substance for
endovascular aneurysm sac ﬁlling. Further research should clarify
the thrombogenicityof theelastomer invivo, aswell as the feasibility
of the novel treatment concept ‘Customized Aortic Repair’ in vivo.Acknowledgements
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